PHOENIX PHARMACEUTICALS INC has a total of 12 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2001. It filed its patents most often in United States, Canada and China. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are GILL PARKASH, ABBVIE BIOTHERAPEUTICS INC and SHANGHAI ZHANGJIANG BIOTECHNOLOGY CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 8 | |
#2 | Canada | 1 | |
#3 | China | 1 | |
#4 | EPO (European Patent Office) | 1 | |
#5 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Microorganisms | |
#5 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Chang Jaw-Kang | 12 |
#2 | Lyu Rong-Ming | 6 |
#3 | Lyu Rong Ming | 1 |
#4 | Lyu Rongming | 1 |
Publication | Filing date | Title |
---|---|---|
CN103703016A | Phoenixin peptides | |
US2008124813A1 | Bead-based radioimmunoassay | |
US2009030178A1 | Cell permeable bioactive peptide conjugates | |
US2006275321A1 | Polypeptide antagonists of HIV-1 Tat protein | |
US2002058620A1 | Cell growth regulation system |